Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06769997.5Aexternal-prioritypatent/EP1885339B1/en
Application filed by Bristol-Myers Squibb Holdings IrelandfiledCriticalBristol-Myers Squibb Holdings Ireland
Publication of CY1116766T1publicationCriticalpatent/CY1116766T1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Η εφεύρεση αναφέρεται σε φαρμακευτικές συνθέσεις του 'Ν-(2-χλωρο-6-μεθυλοφαινυλο)-2-[[6-[4-(2-υδροξυαιθυλο)-1-πιπεραζινυλο]-2-μεθυλο-4- πυριμιδινυλ]αμινο]-5-θειαζολοκαρβοξαμιδίου και σε μεθόδους χρήσης των φαρμακευτικών συνθέσεων στην αντιμετώπιση ογκολογικών και ανοσολογικών ασθενειών.The invention relates to pharmaceutical compositions of 'N- (2-chloro-6-methylphenyl) -2 - [[6- [4- [2 (hydroxyethyl) -1-piperazinyl] -2-methyl-4-pyrimidinyl] amino] -5-thiazolocarboxamide and methods of use of pharmaceutical compositions in the treatment of oncological and immunological diseases.
3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition